We use first- and third-party cookies to provide our services and collect statistical data. By continuing to browse you accept these cookies. More information Accept
About us

Our vision

To be the European leader in pharmaceutical products for
the treatment of the central nervous system (CNS)

Our mission

To offer a wide range of proven, differentiated and affordable
CNS treatment options to patients, healthcare professionals and industry partners

The NuPharm Group, created in 2016 is a strategic combination of leading and experienced European pharmaceutical companies with outstanding development, manufacturing and sales capabilities focused on CNS. NuPharm has 680 employees across its five companies neuraxpharm, Qualigen, FB Health, Laboratorios Lesvi and Inke.

Its dedicated sales presence commercializes branded CNS products, INN generics and nutraceuticals in Europe. Additionally, with an international presence in more than 50 countries, the Group also manufactures finished dosage forms (FDFs) and niche active pharmaceutical ingredients (APIs) in the CNS and the respiratory areas.


nupharm group
is your first
partner of choice
in cns

OUR STRATEGIC PRINCIPLES

  • Market Presence
    with sales forces in our main EU markets to strengthen our international position as a leader in CNS

  • EMPRESA_METAS_STRATEGIC_ALT_LIST02

    R&D Investment 
    into a robust pipeline that broadens our CNS portfolio with differentiated products

  • Partnership 
    with the European community of CNS patients and healthcare professionals

  • Enhancement
    and optimisation of our international portfolio through B2B selling of FDFs and APIs

  • Synergy 
    via backward integration and strengthening operational excellence within the Group

  • Start-up culture
    with a strong focus on quality, collaboration and agility promoting smart solutions that differentiate us from our competitors

The integration of all the companies within
NUPHARM GROUP
allows us to establish growth and cross-business operational synergies in strategic aspects such as R&D, manufacturing, procurement, cross-licensing and geographical expansion

NUPHARM GROUP FAMILY MEMBERS

NuPharm Group owns and operates three European distribution and marketing companies with a special focus on CNS

  • neurax foundation

    Leading CNS generic pharmaceutical company in Germany, specialised in standard and differentiated generics and originals

    More
  • CNS disorders

    Specialised in commercialising medicinal products in Spain with a strategic approach to products for CNS disorders

    More
  • FB Health

    One of the top-selling specialty generic players in Italy with a focus on CNS drugs and nutraceuticals

    More

NuPharm Group also owns and operates two manufacturing plants in Spain

  • Laboratorios Lesvi

    B2B solutions provider dedicated to the development and manufacture of finished dosage forms (FDFs)

    More
  • Inke

    Focused on the development and manufacture of the highest quality active pharmaceutical ingredients (APIs) with complex synthesis processes

    More

NUPHARM GROUP

is your first partner of choice in CNS
More

300M€ Turnover

central nervous system
>100
MOLECULES IN CNS
50%
EUROPE CNS
MARKET
REACHED
680
group employees
25%
SALES & MARKETING EMPLOYEES
NuPharm was created as a holding company and currently consists of neuraxpharm, Qualigen, FB Health, Laboratorios Lesvi and Inke. Through the dedicated commercial sales forces of neuraxpharm, Qualigen and FB Health, NuPharm commercialises branded CNS products, INN generics and nutraceuticals in Germany, Spain, Italy and Poland.

Additionally, through our manufacturing companies Laboratorios Lesvi and Inke, the Group has an international presence in more than 50 countries. We provide industry partners with finished dosage forms (FDFs) across multiple technologies and niche active pharmaceutical ingredients (APIs) using our expertise in the CNS and the respiratory areas.

Global presence

High international presence through selling APIs and FDFs to more than 50 countries

NUPHARM NETWORKED PHARMA